Table 4.
HbA1c and CGM Data in 28 Participants with Type 1 Diabetes.
| Metric | Baseline |
Intervention week 1 |
Intervention week 12 |
|||||
|---|---|---|---|---|---|---|---|---|
| N | Mean (±SD) | Mean (±SD) | Mean change [CI]a | P-valueb | Mean (±SD) | Mean change [CI]a | P-valueb | |
| HbA1c (mmol/mol) | 28 | 57 (8) | NA | 57 (9) | −0.6 [–2.6; 1.3] | .510 | ||
| (DCCT %) | 28 | 7.4 (0.7) | NA | 7.3 (0.8) | −0.1 [–0.2; 0.1] | .510 | ||
| CGM (MBG, mg/dL) | 20 | 175 (29) | 168 (24) | −6.2 [–15.6; 3.1] | .180 | 180 (26) | 5.9 [–3.3; 15] | .195 |
| CGM (CV, %) | 20 | 38.8 (8.9) | 36.7 (9.6) | −2.1 [–5.7; 1.6] | .249 | 35.9 (7.6) | −2.9 [–5.3; –0.4] | .024 |
| CGM (TIR, %) | 20 | 53.9 (16.9) | 57.3 (16.5) | 3.4 [–2.2; 9.1] | .220 | 50.1 (13.6) | −3.8 [–10.0; 2.4] | .214 |
| CGM (TBR level 1, %) | 20 | 2.2 (2.8) | 2.6 (3.0) | 0.4 [–0.9; 1.6] | .556 | 2.2 (2.9) | 0.0 [–0.9; 0.9] | .986 |
| CGM (TBR level 2, %) | 20 | 1.7 (4.6) | 1.8 (5.5) | 0.0 [–0.6; 0.6] | .914 | 1.0 (2.8) | −0.7 [–1.7; 0.3] | .154 |
| CGM (TAR level 1, %) | 20 | 25.9 (10.4) | 26.8 (10.0) | 0.9 [–1.7; 3.5] | .476 | 31.4 (9.8) | 5.6 [1.8; 9.3] | .006 |
| CGM (TAR level 2, %) | 20 | 16.3 (11.4) | 11.6 (8.1) | −4.7 [–10.0; 0.5] | .076 | 15.2 (9.5) | −1.0 [–5.8; 3.8] | .646 |
SD, standard deviation.
Baseline, 1-week, and 12-week results are reported.
a
95% confidence interval, paired z test, compared with baseline.
b
Paired z test, compared with baseline.
HbA1c results are only available for baseline and 12 weeks. CGM data only reported for participants, where sensor data were available for baseline, week 1, and 12 of the intervention.
CGM, continuous glucose monitoring; CV, coefficient of variation; DCCT, Diabetes Control and Complications Trial units, HbA1c, hemoglobin A1c; MBG, mean blood glucose; TAR, time above range; TBR, time below range; TIR, time in range.